Vigilant Biosciences Launches Clinical Studies of Oral Cancer Assay
Vigilant Biosciences has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its registration submission to the.
Industry News
Oral Cancer Test Gets European Conformity (CE) Mark
Vigilant Biosciences has received the European Conformity (CE) mark for its OncAlert Oral Cancer RAPID Test, enabling the company to market the product.
- May 6, 2016
- 1 minute read
Industry News
HPV Antibody May Indicate Cancer Recurrence Risk
HPV infections cause about 80% of oropharyngeal cancers in the United States, according to the National Cancer Institute. More than 25% of these.
- February 9, 2016
- 2 minutes read
Industry News
Biomarkers Tallied for Peri-Implant Disease Potential
Dental implants can be effective in replacing failed or missing teeth, ensuring aesthetics and saving smiles. But poor oral hygiene, residual cement, smoking,.
- October 14, 2015
- 1 minute read
Todays Dental News
Personal Journey Drives Cancer Innovation
Today’s oral cancer detection products typically rely on revealing abnormalities or detecting HPV. Yet these tests aren’t necessarily accurate or timely, discovering dangers.
- August 28, 2015
- 9 minutes read
